What If Your Best Subgroup Is Your Biggest Development Risk?
- 21 hours ago
- 1 min read
A subgroup can make a weak result look promising.
Or it can reveal where the therapy actually works.
The problem is knowing which one you are looking at before it shapes your Phase III strategy, valuation, or indication thesis.
A favorable point estimate is not enough.
A significant result in one subgroup is not enough.
And a forest plot is not proof of treatment-effect modification.
The real test is whether the signal survives.
In this week's Evidence Brief, Rubix LS examines when population heterogeneity becomes a liability, when it becomes a therapeutic opportunity, and what evidence is needed before a subgroup is strong enough to change the development thesis.
Because the subgroup you build around may be the subgroup that breaks the program.
Read the full Evidence Brief below.
